This study was performed for the purpose to evaluate the effect of activin A/BMP-2 chimera (AB204) on cardiovascular system and toxicological effect in beagle dogs. When administered AB204 at the dose of 0.32 mg/kg via intravenous injection in beagle dogs, there were no changes in systolic, diastolic and mean blood pressure as well as in pulse rate, in addition that there were no differences in ORS complex, PR interval, R–R interval, QT interval and QTcV interval on the electrocardiography. Also, when administered AB204 at the doses of 0.25 and 0.5 mg/kg/day via repetitive intravenous injection for 2 weeks, it did not cause any significant changes in general symptoms, weight, food intake, ophthalmologic abnormality, urine, hematology, serum biochemistry, organ weight and autopsy values. Therefore, AB204 did not affect cardiovascular functions including blood pressure, pulse rate and ECG, when administered at the dose of ≤0.32 mg/kg via single intravenous injection in male beagle dogs. When it was administered at the dose of 0.5 mg/kg repetitive intravenous injection for 2 weeks, it did not show any toxicity.
Activin A rhBMP-2 Intravenous administration Cardiovascular function Toxicity In vivo
This is a preview of subscription content, log in to check access.
This work was supported by Mid-career Researcher Program through NRF Grant (2016R1A2B3015048) funded by the Korea government (MSIP).
Compliance with Ethical Standards
Conflict of interest
All authors disclose here that there are no conflicts of interest that could inappropriately have influenced the outcome of the present study.
Axelrad, T. W., & Einhorn, T. A. (2009). Bone morphogenetic proteins in orthopaedic surgery. Cytokine and Growth Factor Reviews,20, 481–488.CrossRefPubMedGoogle Scholar
Stachniak, J. B., Diebner, J. D., Brunk, E. S., & Speed, S. M. (2011). Analysis of prevertebral soft-tissue swelling and dysphagia in multilevel anterior cervical discectomy and fusion with recombinant human bone morphogenetic protein-2 in patients at risk for pseudarthrosis. Journal of Neurosurgery: Spine,14, 244–249.PubMedGoogle Scholar
Scheer, J. K., Dahdaleh, N. S., & Smith, Z. A. (2015). Seroma observed 6 months after anterior lumbar interbody fusion that included use of recombinant bone morphogenetic protein 2. Spine Journal,15, e33.CrossRefPubMedGoogle Scholar
Comer, G. C., Smith, M. W., Hurwitz, E. L., Mitsunaga, K. A., Kessler, R., & Carragee, E. J. (2012). Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: A 10-year cohort controlled study. Spine Journal,12, 881–890.CrossRefPubMedGoogle Scholar
Tannoury, C. A., & An, H. S. (2014). Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine Journal,14, 552–559.CrossRefPubMedGoogle Scholar
Muchow, R. D., Hsu, W. K., & Anderson, P. A. (2010). Histopathologic inflammatory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion. Spine Journal,10, e1–e6.CrossRefPubMedGoogle Scholar
Fu, R., Selph, S., McDonagh, M., Peterson, K., Tiwari, A., Chou, R., et al. (2013). Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: A systematic review and meta-analysis. Annals of Internal Medicine,158, 890–902.CrossRefPubMedGoogle Scholar
Allendorph, G. P., Read, J. D., Kawakami, Y., Kelber, J. A., Isaacs, M. J., & Choe, S. (2011). Designer TGFβ superfamily ligands with diversified functionality. PLoS ONE,6, e26402.CrossRefPubMedPubMedCentralGoogle Scholar
Yoon, B. H., Esquivies, L., Ahn, C., Gray, P. C., Ye, S. K., Kwiatkowski, W., et al. (2014). An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2. Journal of Bone and Mineral Research,29, 1950–1959.CrossRefPubMedPubMedCentralGoogle Scholar
Yoon, B. H., Lee, J. H., Na, K., Cho, J., & Choe, S. (2015). The toxicological evaluation of repetitive 2- and 4-week intravenous injection of activin A/BMP-2 chimera (AB204) into rats. Regulatory Toxicology and Pharmacology,73, 1–8.CrossRefPubMedGoogle Scholar
Lee, J. H., Lee, E. N., Chang, B. S., & Lee, C. K. (2014). Acute intravenous injection toxicity study of escherichia coli-derived recombinant human bone morphogenetic protein-2 in rat. Asian Spine Journal,8, 113–118.CrossRefPubMedPubMedCentralGoogle Scholar
Lee, J. H., Lee, E. N., & Nam, S. H. (2014). The short-term effects of repetitive E. coli-derived rhBMP-2 administration through intravenous injection in rats. Drug and Chemical Toxicology,37, 40–47.CrossRefPubMedGoogle Scholar
Yong, H. E., Murthi, P., Wong, M. H., Kalionis, B., Cartwright, J. E., Brennecke, S. P., et al. (2015). Effects of normal and high circulating concentrations of activin A on vascular endothelial cell functions and vasoactive factor production. Pregnancy Hypertens,5, 346–353.CrossRefPubMedGoogle Scholar
Moura, J., da Silva, L., Cruz, M. T., & Carvalho, E. (2013). Molecular and cellular mechanisms of bone morphogenetic proteins and activins in the skin: Potential benefits for wound healing. Archives of Dermatological Research,305, 557–569.CrossRefPubMedGoogle Scholar
Otsuka, F. (2010). Multiple endocrine regulation by bone morphogenetic protein system. Endocrine Journal,57, 3–14.CrossRefPubMedGoogle Scholar